Composition for cryopreservation comprising nicotinamide, glycerol and red blood cells
View Patent ↗A red blood cell storage composition includes a composition of red blood cells and biochemistry altering reagents, the biochemistry altering reagents being present at a concentration so as to reduce the percent hemolysis of the red blood cells during the freeze-thaw cycle below that of the percent hemolysis of the red blood cells in the absence the biochemistry altering reagents. The red blood cell storage composition preferably includes reagents selected from: modifiers of glycolytic/metabolic components, modifiers of antioxidant potential, effectors of intracellular ionic distribution, modifiers of membrane fluidity, modifiers of cytoskeletal structure, effectors of the cyclooxygenase second messenger pathway, effectors of the lipoxygenase second messenger pathway, effectors of the hexose monophosphate second messenger pathway, effectors of the phosphorylation second messenger pathway, modifiers of specific messenger molecules, and combinations thereof.
1. A red blood cell composition comprising:
(a) red blood cells;
(b) nicotinamide; and
(c) glycerol at a concentration of about 20% glycerol (weight/volume) and that meets the criteria for transfusable blood based on the overall hemolysis and free hemoglobin levels after freezing and thawing.
2. The composition of claim 1 , wherein the nicotinamide and glycerol are present in concentrations so that upon in vitro preservation of the red blood cells at a temperature below the red blood cells' physiological temperature for a period of about 2-7 days, the red blood cells exhibit decreased hemolysis during a freeze-thaw cycle and increased in vitro functional activity when compared to red blood cells preserved under the same conditions but in the absence of nicotinamide.
3. The composition of claim 2 , wherein the red blood cells are preserved at a temperature from about −10° C. to about −193° C.
4. The composition of claim 2 , wherein the red blood cells are preserved at a temperature of about −80° C.
5. The composition of claim 1 , wherein the composition meets the criteria for a transfusable blood unit based on the overall level of hemolysis and residual free hemoglobin levels.
6. The composition of claim 1 , further comprising at least one biochemistry altering reagent selected from the group consisting of pentoxyfylline, flurbiprofen, nikethamide, nifedipine, amiloride, taxol, cytochalasin B, trehalose, ribose, a protease inhibitor, a bioflavonoid, and a bioflavonoid derivative.
7. The composition of claim 6 , wherein the protease inhibitor is leupeptin.
8. The composition of claim 6 , wherein the bioflavonoid derivative is selected from the group consisting of rutin, quercetin, and curcumin.
9. The composition of claim 1 , further comprising at least one additional cryoprotective agent selected from the group consisting of dimethyl sulfoxide, 2,3 butanediol, 1,2-propanediol, 1,3-propanediol, polypropylene glycol, N,N-dimethylacetamide, 1,3,5-trimethyl pentanetriol, hydroxyethyl starch, dextran, polyvinyl pyrrolidone, polyethylene, and polyethylene glycol.
10. The composition of claim 1 , wherein the composition is frozen.